JMP Securities Reiterates Market Outperform Rating on Protagonist Therapeutics (PTGX)

JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating and $58.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).

The analyst commented, “Dr. Scandura highlighted that iron dysregulation and deficiency are very common in PV patients due to uncontrolled red blood cell overproduction and therapeutic phlebotomy, which results in potentially debilitating symptoms of fatigue and poor concentration."

Also, "He expects rusfertide’s mechanism as a mimetic of hepcidin, the key regulator of iron circulation, will normalize iron levels, control HcT, and substantially reduce the phlebotomy rate, which should improve symptoms.”

For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.

Shares of Protagonist Therapeutics closed at $37.75 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Meta plans 'Hatch' AI agent priced at up to $200/month - The Information
• Redwire Defense wins $15.9M Army contract for drone systems